Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) EPS (Basic): 2009-2024

Historic EPS (Basic) for Myriad Genetics (MYGN) over the last 16 years, with Dec 2024 value amounting to -$1.41.

  • Myriad Genetics' EPS (Basic) fell 20.83% to -$0.29 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.33, marking a year-over-year decrease of 238.37%. This contributed to the annual value of -$1.41 for FY2024, which is 55.66% up from last year.
  • As of FY2024, Myriad Genetics' EPS (Basic) stood at -$1.41, which was up 55.66% from -$3.18 recorded in FY2023.
  • In the past 5 years, Myriad Genetics' EPS (Basic) registered a high of -$0.35 during FY2021, and its lowest value of -$3.18 during FY2023.
  • In the last 3 years, Myriad Genetics' EPS (Basic) had a median value of -$1.41 in 2024 and averaged -$1.99.
  • In the last 5 years, Myriad Genetics' EPS (Basic) slumped by 4,583.33% in 2020 and then surged by 88.29% in 2021.
  • Yearly analysis of 5 years shows Myriad Genetics' EPS (Basic) stood at -$2.69 in 2020, then reached -$2.99 in 2020, then surged by 88.29% to -$0.35 in 2021, then tumbled by 297.14% to -$1.39 in 2022, then slumped by 128.78% to -$3.18 in 2023, then spiked by 55.66% to -$1.41 in 2024.